COVID-19 presenting as thrombotic thrombocytopenic purpura (TTP).

Abstract

We present the case of a 39-year-old man with epigastric pain, nausea and vomiting. The patient scored 4 in the Visual Triage Checklist of acute respiratory symptoms; a COVID-19 swab was taken. Prompt review of the peripheral blood smear showed evidence of microangiopathic haemolytic anaemia and thrombocytopenia. Because the patient had a picture of thrombotic thrombocytopenic purpura, plasma exchange and corticosteroids were started immediately. After 3 days, he developed severe ischaemic stroke and his swabs came back positive for COVID-19 by reverse transcription PCR. Therefore, triple therapy was started (lopinavir/ritonavir, ribavirin and interferon beta-1b). White blood cell count reached 50×109/L (normal range, 4.5-11×109/L), mainly neutrophils. All the workup for autoimmune diseases was negative. The patient showed delayed improvement in lactate dehydrogenase, haemoglobin and platelet count until we increased the volume of plasma exchange and subsided the inflammatory response of COVID-19. After that, the patient showed an excellent recovery.

• Authors: Essam Altowyan, Omar Alnujeidi, Atheer Alhujilan, Mohammed Alkathlan
• Journal: BMJ case reports (BMJ Case Rep) Vol. 13 Issue 12 (Dec 17 2020) ISSN: 1757-790X [Electronic] England
• PMID: 33334760 (Publication Type: Case Reports, Journal Article)
• Copyright: © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Drug Combinations
• lopinavir-ritonavir drug combination
• Lopinavir
• Interferon-beta
• Ritonavir

Topics

• Adult
• COVID-19 (complications, diagnosis)
• Drug Combinations
• Humans
• Interferon-beta (therapeutic use)
• Ischemic Stroke (diagnosis, etiology)
• Lopinavir (therapeutic use)
• Male
• Plasma Exchange (methods)
• Purpura, Thrombotic Thrombocytopenic (diagnosis, etiology)
• Ritonavir (therapeutic use)
• SARS-CoV-2
• COVID-19 Drug Treatment